RxDoctor Payments Data

Joseph Forney, MD

Cardiovascular Disease · Little Rock, ARNPI 1003887589

Payments from drug & device makers

$894in general payments, 2019–2025

Across 47 payments — averaging $19.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$221
  • Pfizer$180
  • Novartis$152
  • Sanofi-aventis U.S. LLC$106
  • Johnson & Johnson$80
  • Novo Nordisk$33
  • plus $122 from 6 others

What the payments were for

  • Food & beverage$894100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$894 in reported general payments places this provider in the 20th percentile of 130 cardiovascular disease providers in Arkansas.

See all cardiovascular disease providers in Arkansas

Medicare billing

Part B allowed, 2024
$63,764
Medicare patients
193
Services billed
1,573

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban123$94,513
EntrestoSacubitril/Valsartan42$41,522
Repatha SureclickEvolocumab41$33,947
JardianceEmpagliflozin41$32,748
FarxigaDapagliflozin Propanediol25$14,579
VascepaIcosapent Ethyl15$5,170
Potassium Chloride125$3,232
Ezetimibe141$3,187
Rosuvastatin Calcium208$2,675
Labetalol Hcl87$2,216
Clonidine16$1,799
Omega-3 Acid Ethyl Esters19$1,732
Amlodipine Besylate319$1,664
Losartan Potassium166$1,388
Atorvastatin Calcium165$1,384

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$180$94,513123 claims
NovartisEntresto$152$41,52242 claims
Boehringer IngelheimJardiance$21$32,74841 claims
AstraZenecaFarxiga$28$14,57925 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 130 cardiovascular disease providers in Arkansas.

Other cardiovascular disease in Little Rock

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →